Willis’ $1.2bn Tranzact deal likely precludes more big buys in 2019

wtw cityof london

Willis has followed through on recent signals that it has M&A funds available with the acquisition of Tranzact, a direct-to-consumer healthcare broker, for a price that one estimate said implies 23.7x trailing earnings.

Want to read this article?

Subscribe for FULL access to this article - and ALL our premium content

For details on how to subscribe or for all commercial opportunities, including advertising, please contact:

Spencer Halladey
Commercial director
Email: spencer.halladey@wbmediagroup.com
Tel: +44 (0) 203 934 6687

Andy Stone
Sales manager
Email: andy.stone@wbmediagroup.com
Tel: +44 (0) 203 934 6684

Subscribers get access to:

  • Breaking news by email on all critical issues
  • Trusted analysis and commentary
  • Opinion from market thought-leaders
  • Exclusive data on the industry
  • Daily digital newsletter
  • Full access to our online archive

 

If you are a subscriber you can SIGN IN now for FULL access